Among 39 metastatic GC patients who received 2 or more lines of therapy there was no significant difference in overall survival (OS) between patients with and without PD-L1 expression and/or MLH1/MSH2 loss (P = 0.535) (Figure 3A). This evidence concerns the gene MLH1 and gastric cancer.